ARS Pharmaceuticals Inc (SPRY)
8.16
+0.43
(+5.56%)
USD |
NASDAQ |
Jun 21, 16:00
8.17
+0.01
(+0.12%)
Pre-Market: 20:00
ARS Pharmaceuticals Shareholders Equity (Quarterly): 223.87M for March 31, 2024
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 223.87M |
| December 31, 2023 | 230.76M |
| September 30, 2023 | 237.28M |
| June 30, 2023 | 248.55M |
| Date | Value |
|---|---|
| March 31, 2023 | 261.16M |
| December 31, 2022 | 272.89M |
| June 30, 2022 | -44.03M |
| December 31, 2021 | -31.27M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
-44.03M
Minimum
Jun 2022
272.89M
Maximum
Dec 2022
174.90M
Average
234.02M
Median
Shareholders Equity (Quarterly) Benchmarks
| KalVista Pharmaceuticals Inc | 88.58M |
| Phathom Pharmaceuticals Inc | -148.50M |
| Vera Therapeutics Inc | 353.54M |
| Nuvalent Inc | 675.04M |
| CEL-SCI Corp | 14.30M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 227.58M |
| Total Liabilities (Quarterly) | 3.715M |